Oxycodone behaviors in Cacna1h knockout mice

William B. Lynch1,2, Jacob A. Beierle1,2,3, Rebecca H. Cole1, Rhea Bhandari1, Ahmed Arslan Ph.D.4, Gary Peltz Ph.D.4, and Camron Bryant, Ph.D.1

1Department of Pharmacology and Experimental Therapeutics, Boston University;
2Transformative Training Program in Addiction Science, Boston University; 3T32 Biomolecular Pharmacology Training Program, Boston University; 4Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University

The genetic basis of Opioid use disorder (OUD) is largely unknown. Quantitative trait locus mapping in rodent models offers advantages to human GWAS (controlled sample sizes, controlled environment, within-species gene validation) and can elucidate genetic causes of addiction-relevant model phenotypes. To identify of the genetic basis of OUD-relevant behaviors in mice, we surveyed 29 mouse inbred strains for differences in behaviors following semi-synthetic opioid oxycodone (OXY) administration. Using an OXY conditioned place preference (CPP) experimental design, we found robust strain differences in OXY-induced locomotion, place preference, and state-dependent learning, indicating a heritable basis for these phenotypes. Subsequent haplotype association mapping identified a region on chromosome 17 associated with OXY-induced locomotion containing the candidate gene Cacna1h, which encodes for a voltage-gated calcium channel subunit. To assess differential responses to OXY conditioned reward, tolerance and withdrawal between genotypes, we tested Cacna1h knockout (KO) mice on a mixed 129/C57BL/6N background for OXY CPP and hot plate analgesia, elevated plus maze, and light-dark conflict. There were no significant genotypic differences in distance traveled in response to OXY. Additionally, we observed no genotypic differences in OXY CPP or OXY-induced state-dependent CPP, nor were there any significant differences OXY antinociceptive tolerance or spontaneous withdrawal in the elevated plus maze or the light/dark box. Our negative findings fail to support a role for Cacna1h in opioid addiction model behaviors, with one notable limitation that we have only tested a null mutation on a single genetic background.